Stellar dynamics in young clusters: the formation of massive runaways and very massive runaway mergers

In the present paper we combine an N-body code that simulates the dynamics of young dense stellar systems with a massive star evolution handler that accounts in a realistic way for the effects of stellar wind mass loss. We discuss two topics: 1. The formation and the evolution of very massive stars (with a mass >120 Mo) is followed in detail. These very massive stars are formed in the cluster core as a consequence of the successive (physical) collison of 10-20 most massive stars of the cluster (the process is known as runaway merging). The further evolution is governed by stellar wind mass loss during core hydrogen burning and during core helium burning (the WR phase of very massive stars). Our simulations reveal that as a consequence of runaway merging in clusters with solar and supersolar values, massive black holes can be formed but with a maximum mass of 70 Mo. In small metallicity clusters however, it cannot be excluded that the runaway merging process is responsible for pair instability supernovae or for the formation of intermediate mass black holes with a mass of several 100 Mo. 2. Massive runaways can be formed via the supernova explosion of one of the components in a binary (the Blaauw scenario) or via dynamical interaction of a single star and a binary or between two binaries in a star cluster. We explore the possibility that the most massive runaways (e.g., zeta Pup, lambda Cep, BD+433654) are the product of the collision and merger of 2 or 3 massive stars.Comment: Updated and final versio

Autoantigens in primary biliary cirrhosis

The automimmune liver disease primary biliary cirrhosis (PBC) is characterised by serum autoantibodies directed at mitochondrial and nuclear antigens (seen in most patients and a subset of patients, respectively). The antimitochondrial antibodies (AMA) characteristic of PBC are directed at members of the 2-oxoacid dehydrogenase components of multienzyme complexes; in particular, the E2 and E3 binding protein (E3BP) components of the pyruvate dehydrogenase complex (PDC). The presence of autoantibodies reactive with PDC-E2 and/or E3BP is strongly predictive of the presence of PBC. Therefore, the detection of these antibodies plays a very important role in the diagnosis of PBC. Originally demonstrated using immunofluorescence approaches, AMA can now be detected by the use of commercially available enzyme linked immunosorbent assays (ELISAs). Although the ELISA based approaches have advantages in terms of laboratory practicality, they are slightly less sensitive for the diagnosis of PBC than immunofluorescence (occasional patients with PBC show reactivity with PDC related antigens not present in the antigen preparations available for use with ELISA). Therefore, immunofluorescence should continue to be available as a complementary diagnostic test for use in occasional patients. In a subset of patients with PBC, autoantibodies are directed at increasingly well characterised nuclear antigens. Antinuclear antibody (ANA) positive patients are typically AMA negative. There are no significant differences in disease phenotype between AMA positive and AMA negative groups. At present, the clinical detection of ANA is mostly by Hep2 immunofluorescence, although ELISA kits for individual nuclear antigens are increasingly becoming available. Key Words: liver cirrhosis • biliary • autoimmunity • autoantibod